novster

Ariad Pharma: Professors Patent Pathways and Possibly Profit?

Merck has quite a bit invested in them..

Solar Stocks: Testing the Uptrends

I think you may be wrong on eslr the break out is real on high volume the pull back on lower.There is something going on that you ,or we are not privy to.With silicon dropping and they only use half of what the compettion uses,dont be surprised to see a licensing deal come up..

FDA Calendar Updates: Amylin, Alkermes, Eli Lilly, Cell Therapeutics

does ctic have a potential 2 billion a year sales with pixantrone?

Why Did Dendreon Execs Cash Out on Friday?

I think it would be better to focus on which company would partner and why..The executives always sell when they have a window.Its prudent.Id like to know who would buy them.Would they wait for approval ,or is the pipe line attractive enough..